Long-term Follow-up Study of BHC001 for TDT

Launched by BIORAY LABORATORIES · Mar 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called BHC001 for patients with transfusion-dependent beta-thalassemia (TDT), a type of blood disorder where patients need regular blood transfusions. The main goal of the study is to look at the long-term safety and effectiveness of this treatment after it is given through an intravenous (IV) infusion. The trial is currently recruiting participants aged 18 to 26 years and those older than 12783 years, and both men and women can join.

To be eligible for the trial, participants must have previously received a treatment called BRL-101 for their TDT and must provide written consent to take part in the study. There are no specific exclusion criteria, meaning almost anyone who meets the age and treatment requirements can join. Participants can expect to be monitored over time to assess how well the treatment works and to ensure their safety. This study might help improve treatment options for people living with TDT in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• • 2. Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
• Exclusion Criteria:
• • - There are no exclusion criteria for this study